TABLE 1

Demographic and oncologic characteristics of source population and study subgroup

Embedded Image
  • Data were analyzed by two-tailed Mann-Whitney test, two-tailed square chi test or Fisher’s exact test, as appropriate.

  • a Doxorubicin (or epirubicin)/cyclophosphamide followed by docetaxel; epirubicin/cyclophosphamide/docetaxel; 5-fluorouracil/epirubicin/cyclophosphamide, with or without a subsequent docetaxel; rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone (for non-Hodgkin lymphoma).

  • b Folinate/5-fluorouracil/oxaliplatin; capecitabine/oxaliplatin.

  • c Expressed as doxorubicin myelotoxic equivalents.

  • d Grade 1 diastolic dysfunction at echocardiography.

  • e Nt-proBNP > 125 pg/ml.